Welcome to our dedicated page for Beigene SEC filings (Ticker: ONC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to decode the science-heavy language in BeiGene’s oncology disclosures? Each 10-K details dozens of global clinical trials, milestone obligations, and R&D burn-rates that can stretch past 300 pages. Finding when cash runs out—or which trial just moved to Phase III—takes time investors rarely have.
Stock Titan solves that problem. Our AI-powered summaries turn BeiGene SEC filings explained simply, highlighting the exact paragraph that answers questions like “How much did R&D rise this quarter?” or “Which licensing partner triggered a milestone?” Whether you need the BeiGene annual report 10-K simplified, a BeiGene quarterly earnings report 10-Q filing, or BeiGene 8-K material events explained, the platform delivers real-time alerts the moment they hit EDGAR. You’ll also see BeiGene Form 4 insider transactions real-time, complete with context so you understand why an executive sold shares before a data readout.
Dig deeper without getting lost: track BeiGene insider trading Form 4 transactions to spot buying trends, scan BeiGene proxy statement executive compensation to evaluate alignment, and run instant BeiGene earnings report filing analysis to compare pipeline spending quarter-over-quarter. From understanding BeiGene SEC documents with AI to monitoring BeiGene executive stock transactions Form 4, every filing type is covered and linked to the metrics that matter—so you make informed decisions faster.
BeOne Medicines (ONC) filed a routine Form 4 showing Global Head of R&D Lai Wang sold 1,028 American Depositary Shares on 06/23/2025 at $260 each (≈ $0.27 million) to cover tax withholding linked to vested RSUs. After the sale, he still holds 1,023,529 ordinary shares directly and 731,965 indirectly via Wang Holdings LLC—together ≈ 1.76 million shares. The transaction represents under 1 % of his total ownership and is not considered material.
BeOne Medicines (ONC) filed a routine Form 4 reporting a small insider transaction by President & COO Wu Xiaobin.
On 06/23/2025, Wu disposed of 1,363 American Depositary Shares at $260 per ADS (≈$0.35 million) to satisfy mandatory tax-withholding on vested RSUs. Post-sale holdings remain substantial at 1,228,328 ordinary shares plus 16,365 ADSs (4,000 held indirectly by spouse). No other changes to ownership, compensation, or governance were disclosed.
BeOne Medicines (ONC) filed a routine Form 4 disclosing that Director and Scientific Advisory Board Chair Xiaodong Wang sold an aggregate 2,007 American Depositary Shares (each equal to 13 ordinary shares) on 06/24/2025 under a Rule 10b5-1 plan at prices ranging from $263.40 – $267.81. The total consideration is roughly $0.53 million, representing about 0.3 % of his total beneficial ownership. No new grants, derivative transactions, or governance changes were reported.
BeOne Medicines (ONC) filed a routine Form 4 showing CEO/Director John Oyler’s mandatory tax-withholding sale of 3,174 American Depositary Shares (≈41,262 ordinary shares) on 06/23/2025 at an average price of about $262, totaling roughly $0.83 million.
Post-sale, Oyler still controls ≈54.2 million ordinary shares through direct and indirect holdings, so his ownership percentage is effectively unchanged. No other transactions or material changes were disclosed.
FAQ
What is the current stock price of Beigene (ONC)?
What is the market cap of Beigene (ONC)?
